文献速递胸部肿瘤放疗

化疗免疫治疗联合巩固性胸部放疗治疗广泛期小细胞肺癌:系统综述与Meta分析

Chemoimmunotherapy combined with consolidative thoracic radiotherapy for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
PubMed 文献 · Radiother Oncol · 2023-11-18

该系统综述与Meta分析共纳入15项研究、1033例广泛期小细胞肺癌患者,评估化疗免疫治疗联合巩固性胸部放疗的疗效与安全性。联合治疗显著改善生存(HR=0.52,95%CI:0.39,0.68),6个月和1年总生存率分别为0.89(95%CI:0.77,1.00)和0.77(95%CI:0.72,0.82),≥3级治疗相关不良事件风险无显著增加(RR=1.29,95%CI:0.85,1.98)。

要点

  • 化疗免疫联合巩固性胸部放疗显著改善广泛期小细胞肺癌生存(HR=0.52,95%CI:0.39,0.68)。
  • ≥3级治疗相关不良事件风险无显著增加(RR=1.29,95%CI:0.85,1.98)。
  • ≥3级治疗相关不良事件发生率为0.24(95%CI:0.08,0.39),放射性肺炎发生率为0.03(95%CI:0.01,0.06)。

核心结论

  • 化疗免疫治疗联合巩固性胸部放疗改善广泛期小细胞肺癌患者生存,不良事件可控。
  • 作者指出需要更大样本的进一步研究来证实这些发现。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Embase、Web of Science和Cochrane Library,注册号PROSPERO CRD42023410344。
  • 初筛4677项研究,最终纳入15项研究、共1033例广泛期小细胞肺癌患者。

主要发现

  • 化疗免疫治疗联合巩固性胸部放疗显著改善生存(HR=0.52,95%CI:0.39,0.68)。
  • 6个月总生存率为0.89(95%CI:0.77,1.00),1年总生存率为0.77(95%CI:0.72,0.82)。
  • ≥3级治疗相关不良事件风险无显著增加(RR=1.29,95%CI:0.85,1.98)。
  • 合并6个月无进展生存率为0.67(95%CI:0.47,0.86),1年无进展生存率为0.38(95%CI:0.22,0.55)。
  • ≥3级治疗相关不良事件发生率为0.24(95%CI:0.08,0.39),放射性肺炎发生率为0.03(95%CI:0.01,0.06)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出需要更大样本的进一步研究来证实这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: This study aimed to evaluate the efficacy and safety of chemoimmunotherapy combined with consolidative thoracic radiation therapy (cTRT) in patients with extensive-stage small cell lung cancer (ES-SCLC). METHODS: A meta-analysis was conducted. PubMed, Embase, Web of Science, and the Cochrane Library were searched. The study was registered in PROSPERO (registration no. CRD42023410344). RESULTS: A total of 4677 studies were initially screened and 15 studies encompassing a total of 1033 patients were included. Chemoimmunotherapy combined with cTRT significantly improved survival (HR = 0.52, 95 % CI: 0.39, 0.68) with favorable 6-month (0.89, 95 % CI: 0.77, 1.00) and 1-year (0.77, 95 % CI: 0.72, 0.82) OS, without affecting ≥3 grade TRAEs (RR = 1.29, 95 % CI: 0.85, 1.98). Pooled 6-month and 1-year PFS were 0.67 (95 % CI: 0.47, 0.86) and 0.38 (95 % CI: 0.22, 0.55), respectively. Incidence of ≥3 grade TRAEs was 0.24 (95 % CI: 0.08, 0.39) and radiation pneumonitis was 0.03 (95 % CI: 0.01, 0.06). CONCLUSIONS: Chemoimmunotherapy combined with cTRT improves survival and shows favorable outcomes in ES-SCLC patients, with manageable adverse events. Further research with larger samples is needed to confirm these findings.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Feng B, Zheng Y, Zhang J, et al. Chemoimmunotherapy combined with consolidative thoracic radiotherapy for extensive-stage small cell lung cancer: A systematic review and meta-analysis. Radiother Oncol. 2023. PMID: 37981084. doi:10.1016/j.radonc.2023.110014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。